Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 425

Sort by

Sort Order Select

Journal Articles

Clinical course, predictors of development, and therapeutic response in multiple myeloma with central nervous system involvement

Blood (2025) 146 (Supplement 1): 2225.

https://doi.org/10.1182/blood-2025-2225

Published: 2025

Journal Articles

Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses

Blood (2025) 146 (Supplement 1): 2204.

https://doi.org/10.1182/blood-2025-2204

Published: 2025

Journal Articles

Machine learning–driven prognostication of overall survival at 6 months after CAR-T cell therapy

Blood (2025) 146 (Supplement 1): 2563.

https://doi.org/10.1182/blood-2025-2563

Published: 2025

Journal Articles

Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes

Blood (2025) 146 (Supplement 1): 2179.

https://doi.org/10.1182/blood-2025-2179

Published: 2025

Journal Articles

Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma

Blood (2025) 146 (Supplement 1): 2178.

https://doi.org/10.1182/blood-2025-2178

Published: 2025

Journal Articles

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Blood (2025) 146 (Supplement 1): 686.

https://doi.org/10.1182/blood-2025-686

Published: 2025

Journal Articles

Ultra-sensitive detection of clonal m-protein by mass spectrometry enhances detection of residual disease: Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma

Aarif Ahsan, Adam Luo, Cesar Rodriguez Valdes, Peter Voorhees, Anita D'Souza, Alfred Chung, Sascha Tuchman, Hana Safah, John Mckay, Katja Weisel, Raphael Teipel, Neha Korde, Ravi Vij, Shaji Kumar, Thomas Doerr, Rajvineeth Kumar Pothacamury, Chetasi Talati, Brenda Chyla, Jeremy Ross

Blood (2025) 146 (Supplement 1): 5813.

https://doi.org/10.1182/blood-2025-5813

Published: 2025

Journal Articles

Radiomics-based identification of high-risk disease in newly diagnosed multiple myeloma

Guneet Janda, Emmanuel Contreras Guzman, Michael Howe, Jacob Shreve, Surendra Dasari, Nadine Abdallah, Wilson Gonsalves, Francis Buadi, Joselle Cook, Taxiarchis Kourelis, Suzanne Hayman, Morie Gertz, Rafael Fonseca, Angela Dispenzieri, S. Vincent Rajkumar, Matthew Thorpe, Shaji Kumar, Moritz Binder

Blood (2025) 146 (Supplement 1): 924.

https://doi.org/10.1182/blood-2025-924

Published: 2025

Journal Articles

A new validated staging system for AL amyloidosis with stage IIIc defining an ultra-poor prognostic in systemic AL amyloidosis in the modern treatment era

Blood (2025) 146 (Supplement 1): 577.

https://doi.org/10.1182/blood-2025-577

Published: 2025

Journal Articles

Prophylactic dexamethasone to reduce risk of cilta-cel associated immune effector cell delayed neurotoxicity

Blood (2025) 146 (Supplement 1): 5953.

https://doi.org/10.1182/blood-2025-5953

Published: 2025

Journal Articles

An immune proteomic atlas of 300 million bone marrow cells reveals prognostic cell states in multiple myeloma

Blood (2025) 146 (Supplement 1): 5801.

https://doi.org/10.1182/blood-2025-5801

Published: 2025

Journal Articles

Commpass explorer: An interactive platform to explore clinico-genomic data from newly diagnosed multiple myeloma patients from the commpass observational trial

Wanxing Zhang, Chaitanya Acharya, Steven Foltz, MMRF Immune Atlas Network, David Avigan, Samir Parekh, Ravi Vij, Shaji Kumar, Taxiarchis Kourelis, Sagar Lonial, Hearn Cho, Ioannis Vlachos, Sacha Gnjatic, Li Ding, Manoj Bhasin, George Mulligan

Blood (2025) 146 (Supplement 1): 7470.

https://doi.org/10.1182/blood-2025-7470

Published: 2025

Journal Articles

Cytokine score for prognostication of newly diagnosed multiple myeloma

Arwa Bohra, Surendra Dasari, Moritz Binder, Saurabh Zanwar, Wilson Gonsalves, S. Vincent Rajkumar, Shaji Kumar

Blood (2025) 146 (Supplement 1): 7463.

https://doi.org/10.1182/blood-2025-7463

Published: 2025

Journal Articles

Talquetamab outcomes in relapsed/refractory myeloma with extramedullary and paraskeletal soft tissue plasmacytomas

Blood (2025) 146 (Supplement 1): 825.

https://doi.org/10.1182/blood-2025-825

Published: 2025

Journal Articles

Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

Doris Hansen, Lauren Peres, Danai Dima, Saurabh Zanwar, Omar Alexis Castaneda Puglianini, Alicia Richards, Mahmoud Gaballa, Oren Pasvolsky, Aimaz Afrough, Brett Reid, Ariel Grajales-Cruz, Zhuoer Xie, Utkarsh Goel, Aishwarya Sannareddy, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Hitomi Hosoya, Lekha Mikkilineni, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Peter Cheng, Christian Gordillo, Eli Zolotov, Evguenia Bhurtel, Jeries Kort, Raffaella Cassano Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Rahul Banerjee, Leyla Shune, Ran Reshef, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Frederick Locke, Yi Lin, Surbhi Sidana, Krina Patel

Blood (2025) 146 (Supplement 1): 93.

https://doi.org/10.1182/blood-2025-93

Published: 2025

Journal Articles

Surface protein-focused gene expression analysis identifies prognostic immunophenotypes in newly diagnosed multiple myeloma

Arwa Bohra, Surendra Dasari, Moritz Binder, Nickolas Steinauer, Saurabh Zanwar, Wilson Gonsalves, S. Vincent Rajkumar, Shaji Kumar

Blood (2025) 146 (Supplement 1): 7477.

https://doi.org/10.1182/blood-2025-7477

Published: 2025

Journal Articles

Patterns of progression and clinical outcomes after first relapse in patients with primary plasma cell leukemia

Blood (2025) 146 (Supplement 1): 1036.

https://doi.org/10.1182/blood-2025-1036

Published: 2025

Journal Articles

Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality

Surbhi Sidana, Brett Reid, Danai Dima, Lauren Peres, Mahmoud Gaballa, Rahul Banerjee, Oren Pasvolsky, Aimaz Afrough, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Masooma Rana, Hitomi Hosoya, Lekha Mikkilineni, Vanna Hovanky, Saurabh Zanwar, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Omar Alexis Castaneda Puglianini, Gabriel De Avila, Christian Gordillo, Eli Zolotov, Ariel Grajales-Cruz, Utkarsh Goel, Aishwarya Sannareddy, Jeries Kort, Raffaella Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Zhuoer Xie, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Leyla Shune, Ran Reshef, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Saurabh Dahiya, Frederick Locke, David Miklos, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Yi Lin, Krina Patel, Doris Hansen

Blood (2025) 146 (Supplement 1): 1034.

https://doi.org/10.1182/blood-2025-1034

Published: 2025

Journal Articles

Clinical, anatomic, and histologic determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis: A cohort study of 560 patients

Blood (2025) 146 (Supplement 1): 3962.

https://doi.org/10.1182/blood-2025-3962

Published: 2025

Journal Articles

Cardiac complete response in AL amyloidosis: Phenotypic characteristics, functional recovery, and survival outcomes of 63 patients

Blood (2025) 146 (Supplement 1): 3960.

https://doi.org/10.1182/blood-2025-3960

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Clinical course, predictors of development, and therapeutic response in multiple myeloma with central nervous system involvement

Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses

Machine learning–driven prognostication of overall survival at 6 months after CAR-T cell therapy

Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes

Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Ultra-sensitive detection of clonal m-protein by mass spectrometry enhances detection of residual disease: Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma

Radiomics-based identification of high-risk disease in newly diagnosed multiple myeloma

A new validated staging system for AL amyloidosis with stage IIIc defining an ultra-poor prognostic in systemic AL amyloidosis in the modern treatment era

Prophylactic dexamethasone to reduce risk of cilta-cel associated immune effector cell delayed neurotoxicity

An immune proteomic atlas of 300 million bone marrow cells reveals prognostic cell states in multiple myeloma

Commpass explorer: An interactive platform to explore clinico-genomic data from newly diagnosed multiple myeloma patients from the commpass observational trial

Cytokine score for prognostication of newly diagnosed multiple myeloma

Talquetamab outcomes in relapsed/refractory myeloma with extramedullary and paraskeletal soft tissue plasmacytomas

Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

Surface protein-focused gene expression analysis identifies prognostic immunophenotypes in newly diagnosed multiple myeloma

Patterns of progression and clinical outcomes after first relapse in patients with primary plasma cell leukemia

Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality

Clinical, anatomic, and histologic determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis: A cohort study of 560 patients

Cardiac complete response in AL amyloidosis: Phenotypic characteristics, functional recovery, and survival outcomes of 63 patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only